Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcelo de Souza Fernandes Pereira has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody

    by Wen Luo, Hai-Feng Zhang, Wei Li, Changxin Xu, Hongwen Zhu, Marcelo Pereira, Justin Lyberger, Shiori Eguchi, Yanling Liao, Jeremy M Rosenblum, et al.

    Background: The prognosis of patients with metastatic/relapsed/refractory Ewing sarcoma (ES) is dismal. Natural killer (NK) cells are highly cytotoxic to ES but limited by resistance within the ES tumor microenvironment (TME). Here we sought to overcome ES resistance to NK cells by a combinatorial immunotherapy approach simultaneously enabling NK tumor-specific-targeting via chimeric antigen receptor (CAR) against a novel ES target interleukin-1 receptor accessory protein (IL1RAP), circumventing transforming growth factor beta (TGFβ)-mediated NK immunosuppression by TGFβ1-imprinting, increasing NK cell antibody-dependent cellular cytotoxicity (ADCC) via an anti-GD2 antibody dinutuximab, and improving NK cell persistence and ADCC by an IL-15 agonist, NKTR-255. Methods: Peripheral blood mononuclear cells were expanded into NK and TGFβ1-imprinted-NK (imNK) cells using antigen-presenting feeder cells co-expressing IL-21 and 4–1 BBL. Anti-IL1RAP-CAR messenger RNA was electroporated into NK or imNK cells. In vitro cytotoxicity assays were performed to investigate the efficacy of anti-IL1RAP-CAR-NK/imNK cell alone or combined with NKTR-255 and/or dinutuximab against ES cells. Xenograft mouse models of ES were used to investigate the antitumor efficacy of the combinatorial CAR-NK/imNK cell therapy against ES in vivo. Single-cell RNA sequencing and mass cytometry analyses of cells from xenograft tumors were performed to identify mechanisms of response/resistance to this combinatorial immunotherapy. Results: We found that anti-IL1RAP-CAR-NK cells significantly and specifically enhanced NK cytotoxicity in vitro and decreased tumor growth and lung metastasis in vivo against IL1RAP+ES. TGFβ1-imprinting significantly enhanced in vitro cytotoxicity and tumor infiltration of CAR-NK cells, leading to significantly reduced tumor growth and improved animal survival in the ES orthotopic mouse model. Compared with single agent or double combinations, the triple combination of imprinted-CAR-NK (CAR-imNK) cells and NKTR-255 with dinutuximab had superior antitumor efficacy against IL1RAP+GD2+ ES. Mechanistic studies on single cells from the xenograft tumors revealed increased apoptosis of ES cells, upregulated expression of ligands to NK inhibitory receptors on ES cells, and enhanced mouse macrophage migration in the ES TME in response to the CAR-imNK+NKTR-255+dinutuximab therapy. Conclusions: Our preclinical data demonstrate that combinatorial innate immunotherapy leveraging tumor-targeting TGFβ1-imprinted IL1RAP-CAR-NK cells combined with an IL-15 agonist and an anti-GD2 antibody is a promising novel therapeutic strategy for targeting metastatic/relapsed/refractory ES.

  • Open Access

    Dual-cytokine-armed oncolytic HSV for enhanced tumor immunotherapy

    by Ravi Dhital, Marcelo S.F. Pereira


  • Open Access

    Bringing in cytokine support troops with an OV Trojan horse

    by Dean A. Lee, Marcelo S.F. Pereira

  • Open Access

    Deletion of Glycogen Synthase Kinase 3 Beta Reprograms NK Cell Metabolism

    by Marcelo S. F. Pereira, Kinnari Sorathia, Yasemin Sezgin, Aarohi Thakkar, Colin Maguire, Patrick L. Collins, Bethany L. Mundy-Bosse, Dean A. Lee, Meisam Naeimi Kararoudi

    Loss of cytotoxicity and defective metabolism are linked to glycogen synthase kinase 3 beta (GSK3β) overexpression in natural killer (NK) cells from patients with acute myeloid leukemia or from healthy donors after expansion ex vivo with IL-15. Drug inhibition of GSK3β in these NK cells improves their maturation and cytotoxic activity, but the mechanisms of GSK3β-mediated dysfunction have not been well studied. Here, we show that expansion of NK cells with feeder cells expressing membrane-bound IL-21 maintained normal GSK3β levels, allowing us to study GSK3β function using CRISPR gene editing. We deleted GSK3B and expanded paired-donor knockout and wild-type (WT) NK cells and then assessed transcriptional and functional alterations induced by loss of GSK3β. Surprisingly, our data showed that deletion of GSK3B did not alter cytotoxicity, cytokine production, or maturation (as determined by CD57 expression). However, GSK3B-KO cells demonstrated significant changes in expression of genes related to rRNA processing, cell proliferation, and metabolic function, suggesting possible metabolic reprogramming. Next, we found that key genes downregulated in GSK3B-KO NK cells were upregulated in GSK3β-overexpressing NK cells from AML patients, confirming this correlation in a clinical setting. Lastly, we measured cellular energetics and observed that GSK3B-KO NK cells exhibited 150% higher spare respiratory capacity, a marker of metabolic fitness. These findings suggest a role for GSK3β in regulating NK cell metabolism.


  • Open Access

    Natural Killer Cell Recognition and Control of Epithelial Cancers

    by Marcelo de Souza Fernandez Pereira, David R. Carr, Margaret E. Gatti-Mays, Mallery R. Olsen, Bhuvana A. Setty, Kathryn T. Shahwan, Dean A. Lee

    Natural killer (NK) cells possess an innate ability to recognize cancer and are key mediators of cytotoxic efficacy for anticancer antibodies. Recent advances in the ability to generate, qualify, and safely infuse NK cells have led to a wide variety of clinical trials in oncology. Although their efficacy is best established for liquid cancers, their potential application in solid cancers has received increased attention. Here, we provide general background across a disparate group of exemplary solid tumors for which there is evidence for an NK cell role, discuss NK cell recognition motifs specific to each and murine and human studies of each that are supportive of NK cell adoptive immunotherapy, and end with special considerations relevant to the solid tumor microenvironment.


  • Open Access

    Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV

    by Meisam Naeimi Kararoudi, Shibi Likhite, Ezgi Elmas, Kenta Yamamoto, Maura Schwartz, Kinnari Sorathia, Marcelo de Souza Fernandes Pereira, Yasemin Sezgin, Raymond D. Devine, Justin M. Lyberger, et al.


  • Non-invasive fluorescence imaging for tracking immune cells in preclinical models of immunotherapy

    by Marcelo de Souza Fernandes Pereira, Aarohi Thakkar, Dean Anthony Lee